Garvan Institute Expands Parse Biosciences’ Single-Cell Sequencing Reach in Asia-Pacific
Event summary
- Garvan Institute’s Genomics Platform joins Parse Biosciences’ Certified Service Provider (CSP) Program on July 15, 2026.
- The partnership extends access to Parse’s Evercode WT kits across Australia and the Asia-Pacific region.
- Garvan is a leading Australian medical research institution with expertise in cell sorting, capture, and sequencing.
The big picture
Parse Biosciences’ partnership with Garvan Institute underscores the growing demand for accessible single-cell sequencing technologies. As a QIAGEN company, Parse is positioning itself as a leader in scalable genomic solutions, addressing critical research needs in cancer treatment, tissue repair, and stem cell therapy. This expansion into Asia-Pacific aligns with broader industry trends toward regional collaboration in biomedical innovation.
What we're watching
- Regional Adoption
- How Parse Biosciences will leverage Garvan’s regional presence to accelerate single-cell sequencing adoption in Asia-Pacific.
- Technology Scalability
- Whether the partnership can sustain demand for scalable, high-quality single-cell sequencing projects.
- Competitive Dynamics
- The pace at which Parse Biosciences expands its CSP network to counter competitors in the genomics space.
Related topics